PLTP

Across TCGA pan-cancer cohorts, PLTP Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PLTP data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher PLTP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLTP expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, LUAD, and STAD are the cancer types where PLTP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.037	0.881	<.001	48	view →
LUAD	OS	Median	All	0.421	0.814	<.001	30	view →
STAD	DFS	Median	II,III,IV	0.169	0.641	.007	9	view →
BLCA	OS	Median	IV	0.227	0.602	.019	6	view →
ESCA	DFS	Median	II,III,IV	0.149	0.522	.047	3	view →
SKCM	DFS	Median	II,III,IV	0.208	0.590	.036	3	view →
UCEC	DFS	Median	All	0.951	0.621	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PLTP–KIRC (OS)

Open the KIRC breakdown →